HC Wainwright Issues Pessimistic Forecast for LBRX Earnings

Key Points

• HC Wainwright lowered its LBRX earnings forecasts, projecting a Q3 2026 loss of $1.52 per share versus its prior $0.95 estimate and reducing its FY2026 forecast to a $5.47 loss per share.
• Despite the more pessimistic earnings outlook, HC Wainwright maintained a Buy rating and $60 price target. Overall, analysts rate LB Pharmaceuticals “Moderate Buy,” with a consensus target of $49.62.
• LB Pharmaceuticals previously reported a quarterly loss of $1.71 per share, missing expectations by $0.87, underscoring that the clinical-stage biopharmaceutical company remains unprofitable.

LB Pharmaceuticals Inc (NASDAQ:LBRX - Free Report) - Stock analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for shares of LB Pharmaceuticals in a research report issued to clients and investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.52) per share for the quarter, down from their prior estimate of ($0.95). HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for LB Pharmaceuticals' current full-year earnings is ($4.67) per share. HC Wainwright also issued estimates for LB Pharmaceuticals' Q4 2026 earnings at ($1.49) EPS, FY2026 earnings at ($5.47) EPS, Q1 2027 earnings at ($1.55) EPS, Q2 2027 earnings at ($1.34) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.31) EPS and FY2027 earnings at ($5.48) EPS.

A number of other analysts also recently issued reports on LBRX. Wall Street Zen downgraded LB Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings downgraded shares of LB Pharmaceuticals from a "sell (d+)" rating to a "sell (d)" rating in a research note on Tuesday, August 11th. Wolfe Research initiated coverage on shares of LB Pharmaceuticals in a research note on Tuesday, July 7th. They set an "outperform" rating and a $45.00 price target for the company. BMO Capital Markets increased their price objective on shares of LB Pharmaceuticals from $46.00 to $54.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. Finally, Piper Sandler restated an "overweight" rating and set a $78.00 target price on shares of LB Pharmaceuticals in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, LB Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $49.62.

LB Pharmaceuticals Price Performance

Shares of NASDAQ LBRX opened at $48.80 on Wednesday. LB Pharmaceuticals has a 1-year low of $13.36 and a 1-year high of $50.16. The business's 50 day moving average is $37.73 and its two-hundred day moving average is $30.71. The stock has a market capitalization of $1.57 billion and a P/E ratio of -14.19.

LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.71) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.87).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System raised its holdings in LB Pharmaceuticals by 50,961.3% in the second quarter. California State Teachers Retirement System now owns 531,548 shares of the company's stock worth $16,378,000 after purchasing an additional 530,507 shares in the last quarter. Wellington Management Group LLP lifted its stake in LB Pharmaceuticals by 11.9% during the 2nd quarter. Wellington Management Group LLP now owns 58,891 shares of the company's stock valued at $1,911,000 after acquiring an additional 6,251 shares during the period. Great Lakes Advisors LLC acquired a new stake in LB Pharmaceuticals during the 2nd quarter worth about $987,000. Bank of New York Mellon Corp purchased a new position in LB Pharmaceuticals during the second quarter valued at approximately $1,784,000. Finally, Stempoint Capital LP acquired a new position in shares of LB Pharmaceuticals in the 1st quarter valued at $1,233,000.

LB Pharmaceuticals News Roundup

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target for LB Pharmaceuticals to $60 from $45 and maintained a “Buy” rating. The new target implies additional upside from the recent share price and likely provides the main positive catalyst for LBRX.
• Neutral Sentiment: HC Wainwright’s estimates indicate that LB Pharmaceuticals is still expected to report losses across upcoming quarters, including projected EPS of ($1.52) in Q3 2026, ($1.49) in Q4 2026, ($1.55) in Q1 2027, ($1.34) in Q2 2027, ($1.28) in Q3 2027 and ($1.31) in Q4 2027.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to ($5.47) from ($3.51) and its FY2027 forecast to ($5.48) from ($4.87). The firm also lowered several quarterly estimates, most notably Q3 2026 to ($1.52) from ($0.95), Q4 2026 to ($1.49) from ($1.07), and Q1 2027 to ($1.55) from ($1.13). These revisions signal expectations for deeper losses than previously projected.
• Negative Sentiment: LB Pharmaceuticals previously reported quarterly EPS of ($1.71), missing the consensus estimate of ($0.84) by $0.87. The company is not yet profitable, with analysts forecasting a current-year loss of approximately $4.67 per share.
• Neutral Sentiment: The reported August short-interest data showed zero shares sold short and a zero-day days-to-cover ratio, offering no meaningful indication of short-covering activity or bearish positioning.

LB Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source